Tran Thang, Pham Phuong Thanh, Nguyen Hoa Thi, Hoang Cuc Thi
Department of Medical Oncology 4, National Cancer Hospital, Hanoi, Vietnam.
Ann Med Surg (Lond). 2023 May 24;85(6):3140-3144. doi: 10.1097/MS9.0000000000000902. eCollection 2023 Jun.
Malignant melanoma has a generally poor prognosis and occurs primarily on the skin but may rarely be found in internal organs such as the small intestine, colon, or rectum.
This report presents a case of a 78-year-old male patient with stage IV gastrointestinal melanoma, which is a rare form of melanoma. The patient received first-line pembrolizumab with a complete response.
Surgery plays a crucial role in local and regional control for patients with localized stages. Immune checkpoint inhibitor therapy, including nivolumab or pembrolizumab, is a well-studied and proven effective treatment option for patients with advanced skin melanoma. In this case report, the patient with gastrointestinal melanoma also had a very good response to immunotherapy.
Understanding gastrointestinal melanoma is still limited due to the rarity of this clinical entity. Currently, there are no standard treatment guidelines for this rare group of patients. Immune checkpoint inhibitors could be the preferred first-line therapy for patients with distant metastases.
恶性黑色素瘤的预后通常较差，主要发生于皮肤，但极少见于小肠、结肠或直肠等内脏器官。
本报告呈现了一例78岁男性IV期胃肠道黑色素瘤患者，这是黑色素瘤的一种罕见形式。该患者接受一线帕博利珠单抗治疗后获得完全缓解。
手术在局限性分期患者的局部和区域控制中起着关键作用。免疫检查点抑制剂疗法，包括纳武利尤单抗或帕博利珠单抗，是经充分研究且已证实对晚期皮肤黑色素瘤患者有效的治疗选择。在本病例报告中，胃肠道黑色素瘤患者对免疫疗法也有非常好的反应。
由于这种临床实体罕见，对胃肠道黑色素瘤的了解仍然有限。目前，对于这一罕见患者群体尚无标准治疗指南。免疫检查点抑制剂可能是远处转移患者的首选一线治疗方法。
